scispace - formally typeset
B

Bodhraj Acharya

Researcher at University of Maryland, Baltimore

Publications -  16
Citations -  723

Bodhraj Acharya is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Arthritis & Tevatron. The author has an hindex of 11, co-authored 16 publications receiving 533 citations. Previous affiliations of Bodhraj Acharya include Kyungpook National University Hospital & Kyungpook National University.

Papers
More filters
Journal ArticleDOI

Combination of CDF and D0 W-Boson mass measurements

T. Aaltonen, +779 more
- 23 Sep 2013 - 
TL;DR: In this paper, the mass of the W$ boson at the Fermilab Tevatron has been estimated using direct measurements from the proton-antiproton collision data collected by CDF and D0 experiments.
Journal ArticleDOI

IL-27-induced modulation of autoimmunity and its therapeutic potential

TL;DR: The role of IL-27 is discussed in rheumatoid arthritis, multiple sclerosis, colitis, lupus, psoriasis, type 1 diabetes, and uveitis, where it represents a novel, promising target/agent for the treatment of autoimmune diseases.
Journal ArticleDOI

Secretome analysis of human BMSCs and identification of SMOC1 as an important ECM protein in osteoblast differentiation.

TL;DR: In this article, the authors analyzed the secretory protein profiles of mesenchymal stem cells grown in osteogenic medium (OSM) and identified SPARC-related modular calcium-binding protein 1 (SMOC1), a member of the SPARC family, as a regulator of osteoblast differentiation of BMSCs.
Journal ArticleDOI

Advances in diagnosis of Tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosis.

TL;DR: The use of currently available diagnostic methods and strategies including conventional to recently implemented next-generation sequencing (NGS) methods used to detect Mycobacterium tuberculosis in clinical perspective are reviewed.
Journal ArticleDOI

Cytokine-modulating strategies and newer cytokine targets for arthritis therapy.

TL;DR: The use of anti-inflammatory cytokines or cytokine antagonists delivered via gene therapy has proven to be an effective approach to regulate autoimmunity and to develop appropriate regimens to harness or avoid this effect.